BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome

Reuters

02 Apr

BRIEF-Denali <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome

April 2 (Reuters) - Denali Therapeutics Inc DNLI.O:

DENALI THERAPEUTICS ANNOUNCES INITIATION OF BLA FILING FOR ACCELERATED APPROVAL OF TIVIDENOFUSP ALFA FOR TREATMENT OF HUNTER SYNDROME (MPS II) AND POSITIVE ONGOING INTERACTIONS WITH FDA ON DNL126 THROUGH START PROGRAM
DENALI THERAPEUTICS : EXPECTS TO COMPLETE BLA SUBMISSION IN FIRST HALF OF MAY 2025
DENALI THERAPEUTICS INC: CONTINUES TO PREPARE FOR A POTENTIAL COMMERCIAL LAUNCH IN U.S. IN LATE 2025 OR EARLY 2026

Source text: ID:nGNX7SFxct

Further company coverage: DNLI.O

(((( Reuters.briefs@thomsonreuters.com ;));))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2524673924"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524673924\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2524673924?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-02 20:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524673924","market":"us","top_or_hot":-1,"title":"BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome</title></head><body><p><span>April 2 (Reuters)</span><span> - </span>Denali Therapeutics Inc <span>DNLI.O</span>:</p><ul><li><p>DENALI THERAPEUTICS ANNOUNCES INITIATION OF BLA FILING FOR ACCELERATED APPROVAL OF TIVIDENOFUSP ALFA FOR TREATMENT OF HUNTER SYNDROME (MPS II) AND POSITIVE ONGOING INTERACTIONS WITH FDA ON DNL126 THROUGH START PROGRAM</p></li><li><p>DENALI THERAPEUTICS : EXPECTS TO COMPLETE BLA SUBMISSION IN FIRST HALF OF MAY 2025</p></li><li><p>DENALI THERAPEUTICS INC: CONTINUES TO PREPARE FOR A POTENTIAL COMMERCIAL LAUNCH IN U.S. IN LATE 2025 OR EARLY 2026</p></li></ul><p>Source text: <span>ID:nGNX7SFxct</span></p><p>Further company coverage: <span>DNLI.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-04-02 20:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Denali <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter Syndrome</title></head><body><p><span>April 2 (Reuters)</span><span> - </span>Denali Therapeutics Inc <span>DNLI.O</span>:</p><ul><li><p>DENALI THERAPEUTICS ANNOUNCES INITIATION OF BLA FILING FOR ACCELERATED APPROVAL OF TIVIDENOFUSP ALFA FOR TREATMENT OF HUNTER SYNDROME (MPS II) AND POSITIVE ONGOING INTERACTIONS WITH FDA ON DNL126 THROUGH START PROGRAM</p></li><li><p>DENALI THERAPEUTICS : EXPECTS TO COMPLETE BLA SUBMISSION IN FIRST HALF OF MAY 2025</p></li><li><p>DENALI THERAPEUTICS INC: CONTINUES TO PREPARE FOR A POTENTIAL COMMERCIAL LAUNCH IN U.S. IN LATE 2025 OR EARLY 2026</p></li></ul><p>Source text: <span>ID:nGNX7SFxct</span></p><p>Further company coverage: <span>DNLI.O</span></p><p> (((( Reuters.briefs@thomsonreuters.com ;));))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250402:nFWN3QG0CX:1","article_id":"2524673924","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524673924","pubTimestamp":1743595367,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter SyndromeApril 2 (Reuters) - Denali Therapeutics Inc DNLI.O:DENALI THE","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DNLI":"Denali Therapeutics Inc.","BK4535":"淡马锡持仓","BK4548":"巴美列捷福持仓"},"translate_title":"简介-Denali Therapeutics宣布启动BLA备案，以加速批准Tividenofusp Alfa用于治疗亨特综合征","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DNLI":0.9},"content_text":"BRIEF-Denali Therapeutics Announces Initiation Of BLA Filing For Accelerated Approval Of Tividenofusp Alfa For Treatment Of Hunter SyndromeApril 2 (Reuters) - Denali Therapeutics Inc DNLI.O:DENALI THERAPEUTICS ANNOUNCES INITIATION OF BLA FILING FOR ACCELERATED APPROVAL OF TIVIDENOFUSP ALFA FOR TREATMENT OF HUNTER SYNDROME (MPS II) AND POSITIVE ONGOING INTERACTIONS WITH FDA ON DNL126 THROUGH START PROGRAMDENALI THERAPEUTICS : EXPECTS TO COMPLETE BLA SUBMISSION IN FIRST HALF OF MAY 2025DENALI THERAPEUTICS INC: CONTINUES TO PREPARE FOR A POTENTIAL COMMERCIAL LAUNCH IN U.S. IN LATE 2025 OR EARLY 2026Source text: ID:nGNX7SFxctFurther company coverage: DNLI.O (((( Reuters.briefs@thomsonreuters.com ;));))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}